Dianthus Therapeutics’ (DNTH) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Dianthus Therapeutics (NASDAQ:DNTH) in a report issued on Monday,Benzinga reports. HC Wainwright currently has a $40.00 price objective on the stock.

Other equities analysts have also recently issued reports about the stock. Oppenheimer lifted their price target on shares of Dianthus Therapeutics from $48.00 to $52.00 and gave the stock an “outperform” rating in a research report on Monday. Robert W. Baird initiated coverage on Dianthus Therapeutics in a report on Friday, July 26th. They set an “outperform” rating and a $58.00 target price on the stock. Wedbush lowered their price target on Dianthus Therapeutics from $38.00 to $36.00 and set an “outperform” rating for the company in a report on Friday, August 9th. Raymond James lifted their price objective on Dianthus Therapeutics from $51.00 to $56.00 and gave the company an “outperform” rating in a report on Friday, November 8th. Finally, Baird R W raised Dianthus Therapeutics to a “strong-buy” rating in a research note on Friday, July 26th. Eight equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $46.43.

Dianthus Therapeutics Trading Down 4.8 %

NASDAQ DNTH opened at $26.35 on Monday. Dianthus Therapeutics has a 12 month low of $6.58 and a 12 month high of $33.77. The company has a market capitalization of $779.88 million, a PE ratio of -10.54 and a beta of 1.84. The stock has a 50-day simple moving average of $27.70 and a 200 day simple moving average of $26.64.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($0.74) EPS for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.15). Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. The company had revenue of $2.17 million during the quarter, compared to the consensus estimate of $1.07 million. As a group, sell-side analysts predict that Dianthus Therapeutics will post -2.52 earnings per share for the current fiscal year.

Institutional Trading of Dianthus Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. grew its position in Dianthus Therapeutics by 250.0% in the first quarter. Vanguard Group Inc. now owns 537,828 shares of the company’s stock valued at $16,135,000 after purchasing an additional 384,182 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Dianthus Therapeutics by 860.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 80,935 shares of the company’s stock worth $2,095,000 after buying an additional 72,509 shares during the last quarter. SG Americas Securities LLC grew its holdings in shares of Dianthus Therapeutics by 104.0% in the 3rd quarter. SG Americas Securities LLC now owns 8,839 shares of the company’s stock valued at $242,000 after acquiring an additional 4,506 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. increased its position in shares of Dianthus Therapeutics by 281.9% in the second quarter. Point72 Asia Singapore Pte. Ltd. now owns 39,504 shares of the company’s stock valued at $1,022,000 after acquiring an additional 29,159 shares during the last quarter. Finally, American Century Companies Inc. raised its holdings in Dianthus Therapeutics by 38.6% during the second quarter. American Century Companies Inc. now owns 30,432 shares of the company’s stock worth $788,000 after acquiring an additional 8,473 shares in the last quarter. 47.53% of the stock is currently owned by institutional investors and hedge funds.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.